AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+5.43%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$241M
AUM Growth
+$241M
(-17%)
Cap. Flow
-$25.8M
Cap. Flow
% of AUM
-10.73%
Top 10 Holdings %
Top 10 Hldgs %
81.6%
Holding
34
New
–
Increased
4
Reduced
3
Closed
7
Top Buys
| 1 |
Novo Nordisk
NVO
|
$31M |
| 2 |
Eli Lilly
LLY
|
$5.37M |
| 3 |
argenx
ARGX
|
$1.38M |
| 4 |
Roivant Sciences
ROIV
|
$1.05M |
Top Sells
| 1 |
Biogen
BIIB
|
$14.9M |
| 2 |
Moderna
MRNA
|
$10.3M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$10.3M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$9.63M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$9.38M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Novo Nordisk
NVO
$251B
| $62M | 25.78% |
681,812
+340,906
| +100% | +$31M |
|
2
Merck
MRK
$210B
| $33.9M | 14.09% |
329,200
| – | – |
|
|
3
argenx
ARGX
$43.6B
| $24.2M | 10.06% |
49,238
+2,800
| +6% | +$1.38M |
|
|
4
Eli Lilly
LLY
$657B
| $14.1M | 5.85% |
26,193
+10,000
| +62% | +$5.37M |
|
5
AbbVie
ABBV
$372B
| $13.5M | 5.63% |
90,821
| – | – |
|
6
AstraZeneca
AZN
$248B
| $12.9M | 5.37% |
190,752
| – | – |
|
|
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
| $10.9M | 4.51% |
51,175
| – | – |
|
|
8
Roivant Sciences
ROIV
$8.15B
| $10.7M | 4.44% |
914,023
+89,660
| +11% | +$1.05M |
|
9
89bio
ETNB
$1.34B
| $7.19M | 2.99% |
465,465
| – | – |
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.94M | 2.89% |
78,465
| – | – |
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $6.93M | 2.88% |
57,162
-20,000
| -26% | -$2.42M |
|
12
Vertex Pharmaceuticals
VRTX
$100B
| $6.37M | 2.65% |
18,314
| – | – |
|
13
Axsome Therapeutics
AXSM
$6.05B
| $6.14M | 2.55% |
87,848
| – | – |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $5.06M | 2.1% |
45,000
| – | – |
|
15
Viking Therapeutics
VKTX
$3.04B
| $4.25M | 1.77% |
383,580
| – | – |
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $2.83M | 1.18% |
15,971
| – | – |
|
|
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.17M | 0.9% |
41,600
| – | – |
|
18
Vaxcyte
PCVX
$4B
| $1.97M | 0.82% |
38,555
| – | – |
|
19
Protagonist Therapeutics
PTGX
$3.67B
| $1.87M | 0.78% |
112,340
| – | – |
|
20
Pliant Therapeutics
PLRX
$101M
| $1.73M | 0.72% |
100,000
| – | – |
|
21
Charles River Laboratories
CRL
$8.04B
| $1.35M | 0.56% |
6,905
| – | – |
|
22
Thermo Fisher Scientific
TMO
$186B
| $1.07M | 0.44% |
2,109
-2,979
| -59% | -$1.51M |
|
23
Waters Corp
WAT
$18B
| $780K | 0.32% |
2,845
| – | – |
|
24
Tyra Biosciences
TYRA
$675M
| $623K | 0.26% |
45,253
| – | – |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $615K | 0.26% |
41,261
-128,016
| -76% | -$1.91M |
|